FDA extends review of Praxis Precision Medicines’ NDA for relutrigine, a potential first targeted therapy for SCN2A and SCN8A epileptic encephalopathies, with decision expected December 27, 2026.
Written By: Rishabh Sonawane, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act target action date for Praxis Precision Medicines’ New Drug Application for relutrigine, an investigational precision therapy for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The new target decision date is December 27, 2026, replacing the previous deadline of September 27, 2026.
The extension follows the company’s submission of additional sensitivity analyses based on existing clinical data. The FDA classified the submission as a major amendment, providing the agency with additional time to complete its review.
The FDA did not request new clinical studies and identified no safety, manufacturing, or quality issues. The NDA review remains active, with Praxis continuing to work closely with the agency throughout the review process.
Relutrigine Targets Genetic Epilepsies with No Approved Therapies
Relutrigine is an investigational precision medicine being developed for SCN2A and SCN8A developmental and epileptic encephalopathies, rare genetic neurological disorders caused by pathogenic variants in sodium channel genes. These severe childhood-onset epilepsies are characterized by frequent, treatment-resistant seizures, developmental impairment, cognitive deficits, and significant neurological disability.
There are currently no FDA-approved therapies specifically indicated for SCN2A or SCN8A DEEs, leaving patients dependent on symptomatic seizure management with variable clinical benefit. If approved, relutrigine could become the first targeted treatment for these rare epileptic encephalopathies.
Regulatory Review Continues Without New Clinical Requirements
The FDA’s decision reflects a procedural extension rather than concerns about the application itself. Major amendments commonly trigger a three-month extension under the Prescription Drug User Fee Act to allow sufficient time for review of newly submitted analyses.
According to Praxis, the additional submission consisted solely of sensitivity analyses derived from the existing clinical dataset. The agency did not request additional efficacy or safety studies, suggesting that the current evidence package remains under evaluation rather than requiring further clinical development.
Company Remains Confident in the NDA Submission
Commenting on the review extension, Marcio Souza, President and Chief Executive Officer of Praxis Precision Medicines, said the company remains confident in the overall strength of the relutrigine data package and will continue collaborating with FDA reviewers throughout the regulatory process.
Souza also emphasized the significant unmet medical need in patients with SCN2A and SCN8A DEEs, noting that no approved disease-specific treatment options currently exist for these rare neurological disorders.
Next Milestone Expected in December
Praxis will continue preparing for a potential commercial launch while the FDA completes its review. Unless additional regulatory actions occur, the agency is expected to issue its decision on the relutrigine NDA by December 27, 2026.
The upcoming decision could mark an important milestone for precision medicine in rare epileptic encephalopathies, with the potential to introduce the first approved therapy specifically developed for patients with SCN2A and SCN8A DEEs.
Reference
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.